Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 85

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 85
---
 or unauthorized disclosure of our trade secrets, personal information or other proprietary or sensitive information
or other similar disruptions. If a security breach or other incident were to result in the unauthorized access to or unauthorized use,
disclosure, release or other processing of personal information, it may be necessary to notify individuals, governmental authorities,
supervisory bodies, the media and other parties pursuant to privacy and security laws. We could also incur liability, including litigation
exposure, penalties and fines, and we could become the subject of regulatory action or investigation. Our competitive position could
be harmed and the further development and commercialization of our products and services could be delayed. We maintain cyber liability
insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result
from an interruption or breach of our systems. While we have implemented a cybersecurity risk management program, there can be no assurance
that our cybersecurity risk management program and processes, including our policies, controls or procedures, will be fully implemented,
complied with or effective in protecting our systems and information.

We
may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our
management.

From
time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing
of products, product candidates or technologies. Additional potential transactions that we may consider include a variety of different
business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations
and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures
and may pose significant integration challenges or disrupt our management or business, which could adversely affect our business, financial
condition and results of operations. For example, these transactions may entail numerous operational and financial risks, including:

    ●
    exposure
    to unknown liabilities;

    ●
    disruption
    of our business and diversion of our management’s time and attention in order to develop acquired products, product candidates
    or technologies;

    ●
    incurrence
    of substantial debt or dilutive issuances of equity securities to pay for any of these transactions;

    ●
    higher-than-expected
    transaction and integration costs;

    ●
    write-downs
    of assets or goodwill or impairment charges;

    ●
    increased
    amortization expenses;

    ●